Arvigil

Quick links to important sections

Arvigil

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Arvigil

Quick Facts

Property Description
Active ingredient Armodafinil
Form Oral tablet
Pharmacological class Eugeroic agent (Wakefulness-Promoting Agent)
Common use Counteracting excessive daytime sleepiness (EDS)
Origin Synthetic, enantiopure compound

What Type of Medicine is Armodafinil (Arvigil)?

Armodafinil is a prescription-only, synthetic pharmaceutical substance classified as a eugeroic agent, which is a specialized category of drug designed to promote and sustain wakefulness. This classification indicates its primary function is to mitigate persistent and debilitating excessive daytime sleepiness (EDS) in adults. The drug is clinically recognized for maintaining alertness during the dosing interval, particularly in situations like treating sleepiness associated with shift work disorder.

Armodafinil is considered a member of the broader Central Nervous System (CNS) stimulant class, but it has an atypical pharmacological profile compared to traditional systemic stimulants. Its general purpose is solely focused on supporting the capacity for wakefulness, not on treating underlying causes of sleep disorders.

Composition: The R-enantiomer Distinction

The sole active ingredient in Arvigil is Armodafinil, which is administered as an oral tablet and functions as a single-ingredient product. Armodafinil is a synthetic compound known chemically as the R-enantiomer of the related drug, Modafinil, which is a racemic mixture of two mirror-image molecules. This compositional feature differentiates Armodafinil by providing a more sustained effect.

This distinction establishes Armodafinil as an enantiopure compound, containing only the single isomer associated with the longer half-life, which is one of its primary distinguishing features from its chemical predecessor.

General Purpose of a Wakefulness-Promoting Agent

The general purpose of using an eugeroic agent like Armodafinil is to improve and restore functional alertness during required daytime or work hours. The drug’s mechanism involves binding to the dopamine transporter (DAT) and inhibiting the reuptake of dopamine. This activity supports the patient in maintaining an awake state, directly addressing the core symptom of pathological sleepiness.

Regulatory References

  1. wakefulness
  2. two mirror-image molecules

What side effects are possible with Arvigil?

Possible Side Effects and Safety Information

The safety profile of Armodafinil (Arvigil) is based on frequency classification from clinical studies and serious adverse events reported in post-marketing experience.

Most Common Adverse Reactions

The most frequently observed adverse reactions (occurring in 5% or more of patients in clinical trials) primarily affect the nervous and gastrointestinal systems. These include headache, nausea, dizziness, and insomnia (trouble sleeping).

Serious Systemic and Psychiatric Risks

Serious, rare, and potentially life-threatening reactions have been documented in the post-marketing setting. These include Serious Dermatologic Reactions such as Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN), and Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS). These serious rashes generally appear within the first one to five weeks of treatment initiation. Additionally, Multi-organ Hypersensitivity, Angioedema, and Anaphylaxis have been reported. Cardiovascular risks include chest pain, high blood pressure, and arrhythmias, especially in patients with pre-existing heart disease. The medicine is contraindicated in patients with a known hypersensitivity to Armodafinil or Modafinil. It is also contraindicated in patients with a history of Left Ventricular Hypertrophy or Mitral Valve Prolapse who have experienced the associated syndrome when receiving CNS stimulants.

Population-Specific Safety Considerations

Official labeling mandates specific safety considerations for certain populations. A dose reduction is required for patients with severe hepatic impairment. For females of reproductive potential, the drug may reduce the effectiveness of hormonal contraceptives, and alternative, non-hormonal contraception must be used during treatment and for one month after discontinuation due to the risk of fetal harm. Armodafinil is classified as a federally controlled substance (C-IV) due to the potential for abuse and dependence.

Overdose and Emergency Response

Official Regulatory Overdose Information

An overdose of Arvigil is generally associated with an exaggeration of its wakefulness-promoting effects, primarily affecting the Central Nervous System (CNS) and cardiovascular system. The toxic profile reflects the drug’s pharmacological classification.

Documented Manifestations

Regulatory documentation lists several key manifestations in overdose scenarios. These include pronounced CNS effects such as trouble sleeping (insomnia), restlessness, anxiety, disorientation, and confusion, often escalating to hallucinations or feelings of excitement. Cardiovascular symptoms documented in official labeling include chest pain, fluctuations in heart rhythm such as a fast or slow heartbeat (tachycardia/bradycardia), and increased blood pressure (hypertension). Gastrointestinal disturbances such as nausea and diarrhea may also occur.

Emergency Action and Management

Regulatory information specifies that immediate medical attention must be sought in all cases of suspected overdose. Urgent emergency services must be contacted immediately if the individual exhibits severe complications, including seizure, collapse, trouble breathing, or if they cannot be awakened. Management is defined as primarily supportive care because no specific antidote exists for the toxic effects of Armodafinil overdose. Necessary procedural steps documented in official sources include cardiovascular monitoring and considering the use of activated charcoal or gastric lavage in cases of recent ingestion.

Therapeutic Uses of Arvigil

What Arvigil Treats: Main Uses and Benefits

This medication is commonly used to help manage excessive daytime sleepiness (EDS) in adults, a symptom that creates noticeable physiological strain and interferes with daily functioning. Armodafinil is applied in clinical settings associated with diagnosed chronic conditions, namely narcolepsy, obstructive sleep apnea (OSA), and shift work disorder (SWD).

The primary therapeutic benefit is to provide supportive relief and help maintain a sense of stability when symptoms become temporarily overwhelming. The medication is also relevant in scenarios where residual sleepiness persists in OSA patients despite compliant use of primary therapies like Continuous Positive Airway Pressure (CPAP). This supportive relief contributes to easing the overall symptom load during required periods of wakefulness. It is applied in contexts marked by increased discomfort and tension caused by pathological drowsiness.


Quick Fact: Relief for Pathological Sleepiness

Symptom Targeted Clinical Contexts Patient Benefit
Excessive Daytime Sleepiness (EDS) Chronic Narcolepsy, OSA, or Shift Work Disorder (SWD) Assists with functional stability and alertness
Inappropriate Drowsiness Adjunctive use with primary OSA treatment Helps improve day-to-day comfort during symptomatic periods

Regulatory References

  1. NIH DailyMed Label Overview

Eligibility and Restrictions for Use

Official Eligibility and Restriction Summary

Arvigil (Armodafinil) is indicated for use only in adult patients to promote wakefulness. Use in pediatric patients (under 17 years) is not approved for any indication, as safety and effectiveness have not been established by regulatory authorities.

Populations Explicitly Excluded (Contraindications)

The medicine is contraindicated for any individual with a known history of hypersensitivity to either Armodafinil or Modafinil, or those who have previously experienced a serious systemic reaction (such as severe rash or multi-organ hypersensitivity) while taking either drug.

Populations Requiring Conditional Use

  • Severe Organ Impairment: The dosage must be reduced in patients with severe hepatic impairment. Use in patients with severe renal impairment should proceed with caution.
  • Cardio-Psychiatric History: Patients with a history of recent heart attack, unstable angina, severe hypertension, or psychosis require particular caution and monitoring.
  • Pregnancy and Lactation: Use during pregnancy is generally not recommended unless benefits outweigh risks, and patients of reproductive potential should use non-hormonal contraception due to the drug’s potential to reduce the effectiveness of hormonal birth control. Use is not recommended while breastfeeding.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Arvigil (armodafinil) interacts with numerous medicines primarily by influencing the activity of liver enzymes responsible for drug metabolism. Armodafinil acts as a moderate inducer of Cytochrome P450 (CYP) 3A4/5 and a moderate inhibitor of CYP2C19.


Impact on Co-administered Medicines

This modulation of enzyme activity requires specific consideration when co-administering Arvigil with certain drug classes:

Interaction Mechanism Affected Medicine Categories Practical Implication
CYP3A4/5 Induction Steroidal Contraceptives (e.g., those with ethinyl estradiol), Immunosuppressants (e.g., cyclosporine) May reduce the effectiveness of co-administered drugs. For steroidal contraceptives, alternative or concomitant barrier methods are required during and for one month after Arvigil treatment.
CYP2C19 Inhibition Selected Anticonvulsants (e.g., phenytoin), Proton Pump Inhibitors (e.g., omeprazole), Selected Antidepressants May increase the systemic exposure (concentration) of co-administered drugs, potentially requiring a dosage reduction for the interacting medicine.

Other Documented Interactions

Medicines that are also metabolized by these pathways, such as diazepam, midazolam, triazolam, and clomipramine, may have altered exposure when taken with Arvigil. Dosage adjustments for these sensitive substrates may be necessary based on specific clinical circumstances. The simultaneous use of potent inducers like carbamazepine may reduce the systemic exposure of both Arvigil and the inducer.

Mechanism of Action

How Arvigil Works: Mechanism of Action

Armodafinil's primary action is the reuptake inhibition of the Dopamine Transporter (DAT). This targeted interaction increases the concentration and prolongs the action of dopamine in the synaptic space. This molecular event leads to the indirect activation of key central Orexin (Hypocretin) and Histaminergic neuron systems, which are crucial biological regulators of the wake state.

The heightened signaling from these core neurotransmitter systems converges to engage the entire Ascending Arousal System (AAS). This widespread propagation of excitatory signals throughout the brain shifts the overall physiological state toward elevated central arousal and wakefulness signal propagation, and results in a suppression of inhibitory signals that promote sleep. Crucially, the mechanism is indirect; it relies solely on the functional release of the neurotransmitters it modulates and does not directly activate postsynaptic receptors. This constraint functionally limits the action if the underlying arousal pathways are severely compromised.

Dosage and Administration Information

How to Use Arvigil (Armodafinil): Administration Guidelines

Arvigil (armodafinil) is an oral medication that must be used strictly according to the prescribing information. The instructions below outline the procedures for administration and dosing.

Administration and Timing

The medicine is administered as an oral tablet and may be taken with or without food. Taking the tablet with food may delay the time required to reach peak concentration.

Condition Dose Range Administration Time
Narcolepsy 150 mg to 250 mg Once daily in the morning
Obstructive Sleep Apnea (OSA) 150 mg to 250 mg Once daily in the morning
Shift Work Disorder (SWD) 150 mg Once daily approximately one hour prior to the start of the work shift

Dose Adjustments and Procedural Rules

The maximum recommended daily dose is 250 mg. Dosing adjustments are required for certain patient populations:

  • Geriatric Patients: Lower doses and close monitoring are generally considered appropriate.
  • Severe Liver Impairment: A reduced dose is recommended in patients with severe hepatic impairment.

Missed Dose Instructions: If a dose is missed, it should be taken as soon as the patient remembers, unless it is close to their scheduled bedtime. If it is close to bedtime, the missed dose should be skipped, and the patient should resume the usual schedule the following day. Do not take two doses to compensate for the missed dose.

In the context of OSA, Armodafinil is intended for use adjunctively with other treatments like Continuous Positive Airway Pressure (CPAP); the use of CPAP must be continued and encouraged.

Recent Clinical Evidence

Recent Clinical Evidence

Summary of Research

Studies evaluated the activity of the drug against inflammatory markers. Research has reviewed data from clinical trials to understand the drug's activity profile and its relationship to reports of changes in pain and inflammation levels. The precise mechanism of action is not entirely understood, but research suggests it may involve modulating levels of specific neurotransmitters in the brain, such as dopamine.


Clinical Trial Outcomes

Clinical data largely focuses on Phase III randomized controlled trials (RCTs). These studies investigated patient-reported outcomes using validated scores for symptom severity and quality of life.

Major Findings (Based on RCTs):

Study Type Outcome Evaluated
Phase III RCT Change in validated symptom severity score after 8 weeks, compared to placebo.
Meta-Analysis Association with a change in quality of life scores across pooled data.

In one comprehensive RCT, the study reported a difference in the outcome measure compared to the placebo group, as measured by the validated symptom severity score. A subsequent meta-analysis examined whether there was an association with a change in aggregated quality of life scores; findings for long-term symptom management beyond six months were mixed.


Safety and Tolerability Profile

Research has explored the drug's safety profile and tolerability. Mild gastrointestinal upset and temporary fatigue were among the adverse events observed in the trials, typically reported by under 10% of participants. Individuals with kidney issues were populations of interest for safety monitoring in the research.

Studies also investigated combinations, such as exploring the frequency and severity of flare-ups when the drug was evaluated alongside a standard anti-inflammatory.

Frequently Asked Questions (FAQ)

Common questions about Arvigil (FAQ)

Q: What is the difference between Arvigil and related medicines like Modafinil?

Arvigil contains the single active ingredient Armodafinil, which is a single version of the compound known as the R-enantiomer. Modafinil is a racemic mixture, meaning it contains two versions of the compound. Because Armodafinil has a longer half-life, official documents indicate this chemical property is linked to the drug's sustained activity.

Q: Is Arvigil the same as Armodafinil?

Arvigil is a brand name for the medicine. The active ingredient in the tablet is Armodafinil. Both names refer to the same substance used to promote wakefulness.

Q: Is Arvigil used for anything else besides its main purpose?

Official regulatory documents indicate that Arvigil is only approved to help improve wakefulness in adults who have been diagnosed with excessive sleepiness related to narcolepsy, obstructive sleep apnea (OSA), or shift work disorder (SWD). The official labeling does not include other indications.

Q: How quickly does Arvigil usually start working?

Studies on how the medicine is absorbed show that the maximum concentration of the drug in the bloodstream is typically reached about two hours after it is taken on an empty stomach. Taking the tablet with food may cause this peak time to be delayed.

Q: How long does the effect of Arvigil typically last?

The drug's terminal half-life is approximately 15 hours. This is the time it takes for half of the drug to be eliminated from the body, and this chemical property is linked to the drug's sustained activity.

Q: Can Arvigil affect the quality of sleep that night?

Official product information lists insomnia, or trouble sleeping, as one of the most frequently observed adverse reactions in clinical trials. This is likely related to the drug's wakefulness-promoting properties.

Q: What are the most common mild side effects people talk about with Arvigil?

The most frequently observed adverse reactions, reported by 5% or more of patients in clinical trials, include headache, nausea, dizziness, and insomnia (trouble sleeping).

Q: Is a headache a common side effect of taking Arvigil?

Yes, headache is specifically listed in official product information as the most frequently observed adverse reaction, reported by many patients in clinical trials.

Q: Can Arvigil be taken with over-the-counter pain relievers?

Arvigil is described as influencing the activity of certain liver enzymes that are involved in drug metabolism. This activity may affect the concentration of many other medicines, including some over-the-counter pain relievers. Information regarding co-administration should be reviewed with a healthcare provider.

Q: Are there any specific foods I should avoid while on Arvigil?

Official drug information suggests exercising caution with certain foods that can affect the same liver enzymes that process Arvigil. This includes grapefruit products, as they may influence how the drug is metabolized in the body.

Q: Is it safe to drink alcohol while taking Arvigil?

Official product information notes that the use of Arvigil in combination with alcohol has not been studied, and avoidance is suggested.

Q: What kind of studies support the use of Arvigil?

The efficacy and intended use of the drug were evaluated through evidence from 12-week, randomized, double-blind, placebo-controlled clinical trials. These studies focused on adult patients with excessive sleepiness caused by conditions like narcolepsy, OSA, or SWD.

Q: Does Arvigil cause any problems with blood pressure?

Official labeling includes warnings about cardiovascular risks, which include high blood pressure. Studies have also observed modest increases in blood pressure measurements in some patients. Patients with pre-existing heart or blood pressure conditions are advised in official labeling to use caution and monitoring.

Q: Is it normal to feel a bit anxious when first starting Arvigil?

Official product warnings note that some psychiatric symptoms, such as anxiety, can occur. The drug is classified as affecting the nervous system, and patients should be aware of possible changes in mood or behavior.

Q: Can Arvigil affect liver function?

Arvigil is processed primarily by the liver. Official labeling states that a dosage adjustment is necessary for patients with severe hepatic impairment (severe liver issues). There have also been post-marketing reports of severe reactions, such as multi-organ hypersensitivity, that can involve the liver.

Q: Is there a concern about developing dependence on Arvigil?

Arvigil is classified as a Schedule IV federally controlled substance because it carries a potential for abuse and dependence. Physical dependence is possible, and the potential for withdrawal symptoms upon abrupt cessation after chronic use is a documented concern.

Q: What is the general long-term expectation for using Arvigil?

Clinical studies supporting the drug's use largely focused on 12-week trials. However, some longer-term open-label extension studies indicate that the medicine remains effective and is generally well-tolerated by patients who use it for 12 months or more under medical supervision.

Q: Will Arvigil help me focus better if I don't have a sleep disorder?

Official documents state that the medicine is only indicated to improve wakefulness in patients with specific diagnosed sleep disorders (narcolepsy, OSA, or SWD). It is explicitly stated that it should not be used for general or occasional sleepiness that has not been diagnosed as one of these conditions.

Q: Do people typically take Arvigil every single day?

For most of the approved conditions (narcolepsy and OSA), the medicine is taken once daily in the morning. For shift work disorder, it is taken once daily approximately one hour before the work shift. Usage frequency is determined by the specific condition being treated.

Q: What is the mechanism of action of Arvigil described as?

The drug is described as a wakefulness-promoting agent. While the exact process is not fully known, it is understood to work by being a weak inhibitor of the dopamine reuptake process. This action helps increase signals related to wakefulness in the brain.

Q: What happens when Arvigil wears off?

For patients using the medication to manage excessive sleepiness, their symptoms of sleepiness may return when the medicine's effect diminishes or when it is discontinued. For long-term users, abrupt cessation of the drug may also lead to symptoms of withdrawal.

Q: Is it possible for Arvigil to lose its effectiveness over time?

Official product information notes that patients who have been using the medicine long-term and perceive a decrease in effect may need a medical review.

Q: Is Arvigil available as a generic medicine?

Yes, the active ingredient Armodafinil is listed on the FDA's approved drug product list and is currently available as a generic medicine.

Q: Are there any known interactions between Arvigil and herbal supplements?

Official drug information advises caution with certain herbal products that can affect the same liver enzymes that process Arvigil. For example, the use of St. John’s Wort may influence how the drug is metabolized, potentially affecting its concentration in the body.

Q: What happens to Arvigil in the body after it is taken?

After taking the oral tablet, the drug is absorbed by the body. It is then primarily metabolized (broken down) in the liver by specific enzymes and is later eliminated from the body, mostly via the kidneys as unchanged drug and metabolites.

Q: Are there any restrictions on driving or operating machinery while taking Arvigil?

Official labeling states that driving or performing potentially dangerous activities should be avoided if a patient experiences persistent sleepiness, dizziness, or other central nervous system side effects while using the medicine.

Q: Can Arvigil be taken late in the day?

Official dosing guidelines instruct patients to take the medicine either in the morning (for narcolepsy and OSA) or approximately one hour before the work shift (for SWD). Taking it later than prescribed, particularly close to bedtime, is likely to cause the common side effect of insomnia, or trouble sleeping.

Q: Why does Arvigil have a Black Box Warning, if it does?

The FDA label includes prominent Warnings and Precautions about risks such as Serious Dermatologic Reactions (like SJS) and Psychiatric Symptoms. However, the official product labeling does not contain a Black Box Warning, which is the most severe type of warning.

Q: Is it possible to have a serious interaction with another medicine while taking Arvigil?

Yes, Arvigil can cause serious interactions by influencing liver enzymes that process other drugs. This can, for example, reduce the effectiveness of hormonal contraceptives and can increase the body's exposure to certain other medicines, which may require specific management.

Q: How long does it take for Arvigil to be completely cleared from the body?

The terminal half-life of the drug is approximately 15 hours.

Q: What is the role of clinical trials in the approval of Arvigil?

Clinical trials are an essential part of the regulatory process. The role of these controlled studies is to establish the efficacy (that the drug works as intended) and safety of the drug for the specific conditions it is approved to treat.

Q: Are there any common reasons why a doctor might discontinue Arvigil treatment?

Official guidelines recommend that the drug should be stopped immediately if a patient develops a rash or shows signs of a multi-organ hypersensitivity reaction. Treatment may also be discontinued if the patient experiences new or worsening psychiatric symptoms.

Q: Does Arvigil interact with any common anti-anxiety medications?

Because of its effects on liver enzymes (CYP2C19), Arvigil may interact with certain medicines used for anxiety, such as diazepam. This interaction could potentially increase the concentration of the anti-anxiety medicine in the body, which may require specific management.

How should Arvigil be stored and disposed of?

Storage and Disposal of Arvigil (Armodafinil)

Official Storage Conditions

Arvigil tablets must be stored at Controlled Room Temperature, specifically between 20 C to 25 C (68 F to 77 F). Temperature excursions are permitted from 15 C to 30 C. The medication must be kept in the original container, which should be tightly closed and stored away from excess heat and moisture.

Child-Safety and Security

As a controlled substance, Arvigil must be stored in a secure place and kept strictly out of the reach of children. The container should have a locked safety cap to prevent accidental ingestion or misuse.

Disposal Instructions

Disposal of any unused or expired Arvigil tablets must comply with official guidelines for controlled substances. Consumers are instructed to follow the guidance provided by the U.S. Drug Enforcement Administration (DEA) and relevant state or local pharmaceutical waste disposal programs.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Arvigil found in:

A-Z Index: